Current Management Practices for Endometrial Cancer (EC) in the UK: A National Healthcare Professional Survey (KNOW-EC).

Biomarker DNA polymerase epsilon (POLE) endometrial cancer management mismatch repair deficiency (MMRd) real world practice

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
31 May 2024
Historique:
received: 19 01 2024
revised: 09 05 2024
accepted: 29 05 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 24 7 2024
Statut: aheadofprint

Résumé

The clinical landscape for endometrial cancer in the UK is evolving to include new management guidelines and targeted treatment options. An understanding of current treatment and management practices in the UK will help services plan and adapt to upcoming changes. The purpose of this survey was to understand current and anticipated real-world practices for endometrial cancer care in the UK and potential areas for optimisation. Telephone interviews were conducted in November/December 2021 with UK-based healthcare professionals involved in endometrial cancer management. Questions were aligned with the British Gynaecological Cancer Society/European Society for Medical Oncology recommendations, covering the pathway from diagnosis and treatment to follow-up. A total of 63 healthcare professionals (HCPs) involved in the management of patients with endometrial cancer participated in telephone interviews. The results highlighted variations in management and treatment practices for endometrial cancer and suggest that current UK practice appears to diverge from national and international guidance in some instances. While somatic mismatch repair deficiency testing was used by 89.7% of respondents as mainstream testing, the survey highlighted a lack of access to other key molecular biomarker tests, such as polymerase epsilon (POLE) sequencing (used by only 9.8% of HCPs at the time of the survey). The results highlighted several perceived practical barriers to the swift adoption of new therapeutic options, including funding access, limited staff, treatment-related resources, staff education, and support. Our findings support the need for better access to biomarkers that could enable more effective and targeted treatments.

Identifiants

pubmed: 39048405
pii: S0936-6555(24)00212-7
doi: 10.1016/j.clon.2024.05.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

A George (A)

The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: angela.george@rmh.nhs.uk.

R A Herbertson (RA)

University Hospitals Sussex NHS Foundation Trust, Brighton, UK. Electronic address: rebecca.herbertson@nhs.net.

A Stillie (A)

Edinburgh Cancer Centre, Edinburgh, UK. Electronic address: Alison.stillie@nhslothian.nhs.scot.uk.

S McCormack (S)

GSK UK Ltd, Brentford, UK. Electronic address: stephen.d.mccormack@gsk.com.

A M Drean (AM)

GSK UK Ltd, Brentford, UK. Electronic address: amy.m.drean@gsk.com.

A Wesselbaum (A)

GSK UK Ltd, Brentford, UK. Electronic address: anthony.x.wesselbaum@gsk.com.

E Hudson (E)

Velindre University NHS Trust, Cardiff, UK. Electronic address: emma.Hudson@wales.nhs.uk.

T Miles (T)

NHS South West Genomic Medicine Service Alliance, Bristol, UK. Electronic address: tracie.miles@nhs.net.

N A J Ryan (NAJ)

College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, UK. Electronic address: neil.ryan@ed.ac.uk.

H Maxwell (H)

Dorset County Hospital NHS Foundation Trust, Dorchester, UK. Electronic address: Hilary.Maxwell@dchft.nhs.uk.

L Le Treust (L)

Open Health Evidence and Access, Marlow, UK. Electronic address: lucaletreust@openhealthgroup.com.

M McCormack (M)

University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: mary.mccormack2@nhs.net.

Classifications MeSH